News & events
Mendus AB: Report from the Extraordinary General Meeting of Mendus AB (publ) on 18 November 2022
At the Extraordinary General Meeting (the “EGM”) of Mendus AB (publ), reg. no 556629-1786, (the “Company”) on 18 November 2022 the EGM adopted, inter alia, the following resolution. For more detailed...
Mendus AB: Mendus to host key opinion leader event on immunotherapy for maintenance treatment of Acute Myeloid Leukemia patients in remission
Virtual webinar to take place Wednesday, November 30, 2022 @ 1 PM ET / 7PM CET Upcoming data from Phase 2 ADVANCE II trial of DCP-001 at ASH in December 2022 Mendus AB (“Mendus” publ; IMMU.ST, or...
Mendus AB: Mendus to present data at SITC 2022 demonstrating the potential of the DCOne platform to expand memory NK cells for therapeutic purposes
STIMULATION WITH DCONE CELLS LEADS TO SELECTIVE AND STRONG >200-FOLD MEDIAN EXPANSION OF MEMORY NK CELLS Mendus AB (“Mendus” publ; IMMU.ST), a biopharmaceutical company focused on immunotherapies...
Mendus AB: Mendus to present multiple abstracts at ASH 2022 including an oral presentation of updated AML survival results from the Phase 2 ADVANCE II trial
Mendus AB (“Mendus” publ; IMMU.ST, or “the Company”), a biopharmaceutical company focused on immunotherapies addressing tumor recurrence, today announced that updated results from the Company’s...
Key opinion leader event on immunotherapy for maintenance treatment of Acute Myeloid Leukemia patients in remission
Mendus will host a key opinion leader (KOL) webinar highlighting the current state of maintenance treatment and immunotherapy in acute myeloid leukemia (AML) patients. The event will feature two leading clinical experts, Assoc. Prof. Dr. Amer Zeidan, MBBS, MHS, from the Yale School of Medicine, and Prof. Dr. med. Uwe Platzbecker, from the Leipzig University Hospital.
Keep up to date
Join our mailing list to receive our latest news.